Splash celebration glitter
Pharma

$200M in 5 weeks: Behind RevMed's 'eye-popping' Rasonque debut

Generating $198 million in its first five weeks, Revolution Medicines’ RAS inhibitor daraxonrasib is living up to its much-hyped potential.
Fraiser Kansteiner Nov 5, 2026 11:11am
Image of Zepbound injectible with Eli Lilly oral weight loss drugs
Favicon Fierce Healthcare

Hims & Hers partners with Eli Lilly to sell Zepbound, Foundayo

Nov 6, 2026 4:30pm
CMSgov website with a phone that has the CMS logo in front of it

CMS locks in Medicare drug price negotiations for the long haul

Nov 6, 2026 4:24pm
Jeremy Pope in ViiVs PrEP Wisdom

Jeremy Pope joins ViiV in spreading 'PrEP Wisdom'

Nov 6, 2026 1:44pm
setback chess beat defeat rook break

Moderna's COVID vax leads strong Q3 beat

Nov 6, 2026 12:00pm
showdown clash versus vs crash lightning fight dispute

The Oral GLP-1 Tracker: Foundayo's record, Wegovy pill's rebound

Nov 6, 2026 11:30am
More News

Regulatory tracker: J&J's Rybrevant Faspro pushes into new niche

Nov 6, 2026 10:45am

Novartis confirms several new tumor cases in Zolgensma patients

Nov 6, 2026 9:59am

Boehringer-SBP, Fresenius-WuXi Bio, Evommune—Fierce Pharma Asia

Nov 6, 2026 8:04am

Eli Lilly forces compounding rival to shed weight loss claims

Nov 6, 2026 4:25am